Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70377 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Masaki Kawamata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Convergence Research Promotion Office, Research Institute for Cell Design Medical Science (RICeD), Yamaguchi University, Ube, Yamaguchi, Japan. Hauptthemen laut MEDLINE: RNA, Guide, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, MEXT Promotion of Development of a Joint Usage/Research System Project: Coalition of Universities for Research Excellence Program, the Center for Clinical and Translational Research of Kyushu University Hospital.
Abstract (Originalsprache)
CRISPR–Cas9 has revolutionised genome editing by enabling efficient and programmable modification of defined DNA sequences, with guide RNAs (gRNAs) serving as indispensable elements that direct Cas9 to specific genomic loci. Initially regarded as auxiliary components, gRNAs are now recognized as critical determinants of editing efficiency and specificity and have attracted growing attention as independent targets for engineering. Chemical modification, sequence optimisation, and structural alteration of gRNAs have been shown to enhance on‐target activity, suppress off‐target effects and cytotoxicity, and even achieve allele‐selective precision editing in a programmable manner. Moreover, advances in artificial intelligence and machine learning have markedly improved the predictive accuracy of gRNA design through large‐scale data analysis. Despite rapid progress, a consolidated review that integrates chemical, structural, and computational advances in gRNA engineering and highlights their translational potential for therapeutic genome editing has been lacking. This review uniquely addresses that gap by presenting an integrated framework that connects molecular design principles with clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Convergence Research Promotion Office, Research Institute for Cell Design Medical Science (RICeD), Yamaguchi University, Ube, Yamaguchi, Japan.
- Division of Organogenesis and Regeneration, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
- Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
ORCID-Profile: Masaki Kawamata, Satoshi Niwa, Atsushi Suzuki
Förderung
- Japan Society for the Promotion of Science
- MEXT Promotion of Development of a Joint Usage/Research System Project: Coalition of Universities for Research Excellence Program
- the Center for Clinical and Translational Research of Kyushu University Hospital
- the Fukuoka Financial Group Enterprise Development Foundation (KYUTEC)
- the Medical Research Center Initiative for High Depth Omics
- the Takeda Science Foundation (to M.K., and A.S.), the Uehara Memorial Foundation
- Naito Foundation
Zitieren
APA
Kawamata, M., Niwa, S., & Suzuki, A. (2026). Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70377
Vancouver
Kawamata M, Niwa S, Suzuki A. Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70377
BibTeX
@article{Kawamata2026,
author = {Kawamata, Masaki and Niwa, Satoshi and Suzuki, Atsushi},
title = {Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70377}
}
EUVIMED